Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Parabilis Medicines Updates Executive Leadership Team | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Parabilis Medicines Updates Executive Leadership Team

Names New Chief Business and Strategy Officer, Chief Financial Officer.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Parabilis Medicines, a clinical-stage biotechnology company focused on developing peptide-based cancer therapies, has appointed Helen Ho as Chief Business and Strategy Officer and promoted Thomas Kotarakos to Chief Financial Officer.

Dr. Helen Ho, Chief Business and Strategy Officer

Ho joins Parabilis with more than 20 years of experience in biopharmaceutical strategy and corporate development. She most recently served as chief business officer at Blueprint Medicines, where she helped lead corporate strategy and executed more than a dozen transactions that generated over $1 billion in proceeds. Earlier in her career, she held corporate development roles at TCR2 Therapeutics and Agios Pharmaceuticals.

In her new role, Ho will oversee Parabilis’s growth strategy, business development, and portfolio management, as well as corporate communications, alliance management, and competitive intelligence. She holds a Ph.D. in cell biology from Yale University and a bachelor’s degree in biochemistry from the University of California, Los Angeles.

Thomas Kotarakos, Chief Financial Officer

Kotarakos was promoted after holding senior finance roles at Parabilis since joining the company in 2021. He has overseen several private financings, including the company’s $305 million Series F round completed in January. As chief financial officer, he will continue to lead financial strategy, investor relations, and operational functions, including IT and facilities.

Before joining Parabilis, Kotarakos served as senior vice president of finance and business operations at Codiak BioSciences and previously held senior finance positions at Seres Therapeutics. He is a certified public accountant and holds undergraduate and master’s degrees in accounting from Bentley University.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics